根据数据统计，截至2025年10月底，创新药上市公司基本披露三季报。其中，前三季度创新药板块整体营收大幅增长，展现强劲的创新活力。如信达生物、君实生物、荣昌生物、贝达药业、泽璟制药、艾力斯、百利天恒、海创药业、亚虹医药、迈威生物、神州细胞、复宏汉霖、诺诚健华、三生国健、特宝生物、科兴制药、苑东生物、海思科等一批创新药企业创新药价值正在加速释放。以荣昌生物为例，2025年前三季度公司实现收入17.2...
Source Link根据数据统计，截至2025年10月底，创新药上市公司基本披露三季报。其中，前三季度创新药板块整体营收大幅增长，展现强劲的创新活力。如信达生物、君实生物、荣昌生物、贝达药业、泽璟制药、艾力斯、百利天恒、海创药业、亚虹医药、迈威生物、神州细胞、复宏汉霖、诺诚健华、三生国健、特宝生物、科兴制药、苑东生物、海思科等一批创新药企业创新药价值正在加速释放。以荣昌生物为例，2025年前三季度公司实现收入17.2...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.